A Study of Galantamine Used to Treat Patients With Mild to Moderate Alzheimer's Disease

• Status: Terminated
• Trial end date: 2012-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the effectiveness and safety of 2 years of treatment with galantamine as compared with placebo of patients who have mild to moderately severe Alzheimer's disease (AD).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Janssen Research & Development, LLC
• Treatments: Galantamine

Criteria

Inclusion Criteria:

• Outpatients

• diagnosed with mild to moderately-severe, probable or possible AD, established in accordance with the criteria defined by the National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer's Disease Related Disorders Association or the Diagnostic and Statistical Manual, Fourth Edition

• living with or have regular and frequent visits from a responsible caregiver.

Exclusion Criteria:

• Neurodegenerative disorders other than AD, such as Parkinson's Disease, Frontotemporal Dementia or Huntington's disease

• Any of specified conditions which may contribute to dementia

• any of specified coexisting diseases, including significant cardiovascular disease.